Free Access
Med Sci (Paris)
Volume 31, Number 4, Avril 2015
Page(s) 423 - 431
Section M/S Revues
Published online 08 May 2015
  1. Arrowsmith J. A decade of change. Nat Rev Drug Discov 2012 ; 11 : 17–18. [CrossRef] [PubMed] [Google Scholar]
  2. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 2013 ; 18 : 1067–1073. [CrossRef] [PubMed] [Google Scholar]
  3. Prudent R, Vassal-Stermann E, Nguyen CH, et al. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res 2012 ; 72 : 4429–4439. [CrossRef] [PubMed] [Google Scholar]
  4. Moucadel V, Prudent R, Sautel CF, et al. Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget 2011 ; 2 : 997–1010. [PubMed] [Google Scholar]
  5. Prudent R, Moucadel V, Nguyen CH, et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010 ; 70 : 9865–9874. [CrossRef] [PubMed] [Google Scholar]
  6. Lopez-Ramos M, Prudent R, Moucadel V, et al. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights. FASEB J 2010 ; 24 : 3171–3185. [CrossRef] [PubMed] [Google Scholar]
  7. Prudent R, Hasenknopf B, Cochet C Les polyoxométallates : des inhibiteurs inorganiques de la protéine kinase CK2. Med Sci (Paris) 2008 ; 24 : 1012–1014. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. Prudent R, Moucadel V, Laudet B, et al. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 2008 ; 15 : 683–692. [CrossRef] [PubMed] [Google Scholar]
  9. Prudent R, Cochet C. New protein kinase CK2 inhibitors: jumping out of the catalytic box. Chem Biol 2009 ; 16 : 112–120. [CrossRef] [PubMed] [Google Scholar]
  10. Hibert MF. French/European academic compound library initiative. Drug Discov Today 2009 ; 14 : 723–725. [CrossRef] [PubMed] [Google Scholar]
  11. Prudent R, Soleilhac E, Barette C, et al. Les criblages phénotypiques ou comment faire d’une pierre deux coups. Med Sci (Paris) 2013 ; 29 : 897–905. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Hoang TMN, Favier B, Valette A, et al. Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases. Cell Cycle 2009 ; 8 : 765–772. [CrossRef] [PubMed] [Google Scholar]
  13. Camara D, Bisanz C, Barette C, et al. Inhibition of p-aminobenzoate and folate syntheses in plants and apicomplexan parasites by natural product rubreserine. J Biol Chem 2012 ; 287 : 22367–22376. [CrossRef] [PubMed] [Google Scholar]
  14. Boussouar A, Barette C, Nadon R, et al. Acacetin and chrysin, two polyphenolic compounds, alleviate telomeric position effect in human cells. Mol Ther Nucleic Acids 2013 ; 2 : e116. [CrossRef] [PubMed] [Google Scholar]
  15. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 ; 105 : 2640–2653. [CrossRef] [PubMed] [Google Scholar]
  16. Kawasumi M, Nghiem P. Chemical genetics: elucidating biological systems with small-molecule compounds. J Invest Dermatol 2007 ; 127 : 1577–1584. [CrossRef] [PubMed] [Google Scholar]
  17. O’Connor CJ, Laraia L, Spring DR. Chemical genetics. Chem Soc Rev 2011 ; 40 : 4332–4345. [CrossRef] [PubMed] [Google Scholar]
  18. McPherson A, Nguyen C, Cudney R, et al. The role of small molecule additives and chemical modification in protein crystallization. Cryst Growth Des 2011 ; 11 : 1469–1474. [CrossRef] [Google Scholar]
  19. Laramas M, Pasquier D, Filhol O, et al. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007 ; 43 : 928–934. [CrossRef] [PubMed] [Google Scholar]
  20. Giusiano S, Cochet C, Filhol O, et al. Protein kinase CK2alpha subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays. Eur J Cancer 2011 ; 47 : 792–801. [CrossRef] [PubMed] [Google Scholar]
  21. Buchou T, Cochet C. La protéine kinase CK2, une enzyme qui cultive la différence. Med Sci (Paris) 2003 ; 19 : 709–716. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  22. Filhol O, Martiel JL, Cochet C. Protein kinase CK2: a new view of an old molecular complex. EMBO Rep 2004 ; 5 : 351–355. [CrossRef] [PubMed] [Google Scholar]
  23. Laudet B, Barette C, Dulery V, et al. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. Biochem J 2007 ; 408 : 363–373. [CrossRef] [PubMed] [Google Scholar]
  24. Laudet B, Prudent R, Filhol O, et al. Des agents thérapeutiques ciblant des interactions protéine-protéine. Med Sci (Paris) 2007 ; 23 : 273–278. [Google Scholar]
  25. Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery-past, present and future. Nat Rev Drug Discov 2014 ; 13 : 588–602. [CrossRef] [PubMed] [Google Scholar]
  26. Brodin P, Del Nery, Elaine, Soleilhac E. Criblage phénotypique à haut contenu pour la chémobiologie et ses enjeux. Med Sci (Paris) 2015 ; 31 : 187–196. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  27. Vassal E, Barette C, Fonrose X, et al. Miniaturization and validation of a sensitive multiparametric cell-based assay for the concomitant detection of microtubule-destabilizing and microtubule-stabilizing agents. J Biomol Screen 2006 ; 11 : 377–389. [CrossRef] [PubMed] [Google Scholar]
  28. Eggert US, Mitchison TJ. Small molecule screening by imaging. Curr Opin Chem Biol 2006 ; 10 : 232–237. [CrossRef] [PubMed] [Google Scholar]
  29. Korn K, Krausz E. Cell-based high-content screening of small-molecule libraries. Curr Opin Chem Biol 2007 ; 11 : 503–510. [CrossRef] [PubMed] [Google Scholar]
  30. Soleilhac E, Nadon R, Lafanechere L. High-content screening for the discovery of pharmacological compounds: advantages, challenges and potential benefits of recent technological developments. Expert Opin Drug Discov 2010 ; 5 : 135–144. [CrossRef] [PubMed] [Google Scholar]
  31. Martinez A, Soleilhac E, Barette C, et al. Novel synthetic pharmacophores inducing a stabilization of cellular microtubules. Curr Cancer Drug Targets 2014 ; 15 : 2–13. [CrossRef] [Google Scholar]
  32. Lo E, Soleilhac E, Martinez A, et al. Intensity quantile estimation and mapping: a novel algorithm for the correction of image non-uniformity bias in HCS data. Bioinforma Oxf Engl 2012 ; 28 : 2632–2639. [CrossRef] [PubMed] [Google Scholar]
  33. Murie C, Barette C, Lafanechere L, et al. Single assay-wide variance experimental (SAVE) design for high-throughput screening. Bioinforma Oxf Engl 2013 ; 29 : 3067–3072. [CrossRef] [Google Scholar]
  34. Murie C, Barette C, Lafanechère L, et al. Control-plate regression (CPR) normalization for high-throughput screens with many active features. J Biomol Screen 2014 ; 19 : 661–671. [CrossRef] [PubMed] [Google Scholar]
  35. Murie C, Barette C, Button J, et al. Improving detection of rare biological events in high-throughput screens. J Biomol Screen 2014 ; 20 : 230–241. [CrossRef] [PubMed] [Google Scholar]
  36. Thomas CJ, Auld DS, Huang R, et al. The pilot phase of the NIH chemical genomics center. Curr Top Med Chem 2009 ; 9 : 1181–1193. [CrossRef] [PubMed] [Google Scholar]
  37. Voisset C, Blondel M. Chémobiologie à l’happy hour : la levure comme modèle de criblage pharmacologique. Med Sci (Paris) 2014 ; 30 : 1161–1168. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  38. Mahuteau-Betzer F. Chimiothèque Nationale : avancées et perspectives. Med Sci (Paris) 2015 ; 31 : 417–422. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  39. Vidalain PO, Lucas-Hourani M, Helynck O, Tangy F, Munier-Lehmann H. Activation de la réponse innée antivirale par des inhibiteurs de la biosynthèse des pyrimidines : les surprises d’un criblage phénotypique. Med Sci (Paris) 2015 ; 31 : 98–104. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.